New England Research & Management Inc. cut its stake in shares of Pfizer Inc. (NYSE:PFE) by 2.0% in the 1st quarter, Holdings Channel reports. The institutional investor owned 72,109 shares of the biopharmaceutical company’s stock after selling 1,479 shares during the quarter. Pfizer makes up 1.4% of New England Research & Management Inc.’s holdings, making the stock its 14th biggest holding. New England Research & Management Inc.’s holdings in Pfizer were worth $2,613,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Kinloch Capital LLC purchased a new stake in Pfizer during the 4th quarter worth $25,000. Alpha DNA Investment Management LLC bought a new position in Pfizer in the 4th quarter worth about $26,000. Penbrook Management LLC bought a new position in shares of Pfizer in the fourth quarter valued at approximately $27,000. Orion Capital Management LLC bought a new position in shares of Pfizer in the fourth quarter valued at approximately $29,000. Finally, Merrion Investment Management Co LLC bought a new position in shares of Pfizer in the fourth quarter valued at approximately $30,000. 67.36% of the stock is owned by institutional investors.
Shares of NYSE:PFE traded up $0.09 during trading on Monday, hitting $38.66. 421,162 shares of the company’s stock were exchanged, compared to its average volume of 31,941,344. The company has a market cap of $215.63 billion, a price-to-earnings ratio of 24.88, a PEG ratio of 2.79 and a beta of 0.70. The business’s 50-day simple moving average is $35.49 and its 200 day simple moving average is $36.60. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.40 and a quick ratio of 1.13. Pfizer Inc. has a 52-week low of $31.61 and a 52-week high of $43.08.
A number of equities research analysts have issued reports on PFE shares. Berenberg Bank reiterated a “neutral” rating and issued a $38.00 target price on shares of Pfizer in a research report on Tuesday, March 23rd. Royal Bank of Canada assumed coverage on shares of Pfizer in a research report on Wednesday, April 7th. They issued a “sector perform” rating and a $42.00 price target on the stock. The Goldman Sachs Group set a $41.00 price target on shares of Pfizer and gave the company a “neutral” rating in a report on Tuesday, April 6th. Mizuho lowered their price target on shares of Pfizer from $44.00 to $42.00 and set a “buy” rating for the company in a research report on Wednesday, February 3rd. Finally, JPMorgan Chase & Co. set a $36.00 price objective on shares of Pfizer and gave the company a “neutral” rating in a report on Wednesday, February 3rd. Eleven equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $38.47.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands.
Recommended Story: Index Funds
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.